212 related articles for article (PubMed ID: 8454873)
1. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
Friedman PN; Chace DF; Trail PA; Siegall CB
J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.
Siegall CB; Chace D; Mixan B; Garrigues U; Wan H; Paul L; Wolff E; Hellström I; Hellström KE
J Immunol; 1994 Mar; 152(5):2377-84. PubMed ID: 8133048
[TBL] [Abstract][Full Text] [Related]
3. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.
Haggerty HG; Warner WA; Comereski CR; Peden WM; Mezza LE; Damle BD; Siegall CB; Davidson TJ
Toxicol Pathol; 1999; 27(1):87-94. PubMed ID: 10367679
[TBL] [Abstract][Full Text] [Related]
4. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells.
Friedman PN; McAndrew SJ; Gawlak SL; Chace D; Trail PA; Brown JP; Siegall CB
Cancer Res; 1993 Jan; 53(2):334-9. PubMed ID: 8417827
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen.
Siegall CB
Semin Cancer Biol; 1995 Oct; 6(5):289-95. PubMed ID: 8562906
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.
Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I
Cancer Res; 1992 Jun; 52(11):3189-93. PubMed ID: 1591729
[TBL] [Abstract][Full Text] [Related]
8. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.
Francisco JA; Gilliland LK; Stebbins MR; Norris NA; Ledbetter JA; Siegall CB
Cancer Res; 1995 Jul; 55(14):3099-104. PubMed ID: 7541711
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
Siegall CB; Gawlak SL; Chin JJ; Zoeckler ME; Kadow KF; Brown JP; Braslawsky GR
Bioconjug Chem; 1992; 3(4):302-7. PubMed ID: 1390985
[TBL] [Abstract][Full Text] [Related]
10. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs.
Siegall CB; Liggitt D; Chace D; Mixan B; Sugai J; Davidson T; Steinitz M
Clin Cancer Res; 1997 Mar; 3(3):339-45. PubMed ID: 9815690
[TBL] [Abstract][Full Text] [Related]
11. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
[TBL] [Abstract][Full Text] [Related]
12. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy.
Siegall CB; Haggerty HG; Warner GL; Chace D; Mixan B; Linsley PS; Davidson T
J Immunol; 1997 Nov; 159(10):5168-73. PubMed ID: 9366448
[TBL] [Abstract][Full Text] [Related]
13. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
Batra JK; Kasprzyk PG; Bird RE; Pastan I; King CR
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5867-71. PubMed ID: 1352878
[TBL] [Abstract][Full Text] [Related]
14. Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
Siegall CB
Recent Results Cancer Res; 1996; 140():51-60. PubMed ID: 8787077
[No Abstract] [Full Text] [Related]
15. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.
Siegall CB; Liggitt D; Chace D; Tepper MA; Fell HP
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9514-8. PubMed ID: 7937798
[TBL] [Abstract][Full Text] [Related]
16. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent.
Debinski W; Pastan I
Cancer Res; 1992 Oct; 52(19):5379-85. PubMed ID: 1394141
[TBL] [Abstract][Full Text] [Related]
17. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
18. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
Wolf P; Alt K; Bühler P; Katzenwadel A; Wetterauer U; Tacke M; Elsässer-Beile U
Prostate; 2008 Feb; 68(2):129-38. PubMed ID: 18044731
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.
Posey JA; Khazaeli MB; Bookman MA; Nowrouzi A; Grizzle WE; Thornton J; Carey DE; Lorenz JM; Sing AP; Siegall CB; LoBuglio AF; Saleh MN
Clin Cancer Res; 2002 Oct; 8(10):3092-9. PubMed ID: 12374676
[TBL] [Abstract][Full Text] [Related]
20. Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.
Kuan CT; Pastan I
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):974-8. PubMed ID: 8577771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]